Three months ago Inogen told investors its turnaround would take longer than promised, cutting its full-year revenue outlook and guiding the third quarter to roughly flat sales. The stock has since climbed about 21% while the S&P 500 went nowhere. That gap is the story heading into Thursday's report, due after the close on November 5. The market appears to have accepted the lower bar and focused on improving profitability. Now the company has to show that the bar was set low enough.
The revenue math is the first issue. Management guided third-quarter revenue to about $92.4 million, essentially matching the year-ago quarter. Yet consensus sits near $98.2 million, well above the company's own figure. The full-year picture is similar. Analysts are near $369 million, above the revised $355 million to $361 million range and closer to the original $366 million to $373 million outlook that was withdrawn. Either some estimates were not updated after the cut, or analysts doubt management's caution. Either way, a print near guidance could look like a miss on paper even if the company delivers what it promised. Last year's third quarter produced a loss of 20 cents a share. Narrowing that meaningfully would support the profitability argument.
The prior call offers a clear checklist. The guidance cut came from channel mix and international timing, not weak patient demand. Portable oxygen concentrator units rose 12% overall last quarter, and U.S. units grew at a high single-digit rate. The problem is where those units go. Home medical equipment providers are increasingly prescribing portable units from day one, which erodes Inogen's direct-to-consumer and rental businesses. Management conceded this shift is happening faster than expected. Rental revenue fell 12% in the second quarter, after declines of roughly 4% to 5% in the prior two quarters. A further steepening would suggest the erosion is structural rather than a passing adjustment. Any detail on options for the rental business from the new leadership, including newly appointed COO Andy Reding, would matter.
International is the second swing factor. It has been the bright spot, with ten straight quarters of double-digit growth, and second-quarter sales rose 15% to $41.3 million. Management warned that distributor inventory reductions, delayed tenders and distributor consolidation would weigh on the second half. It described the destocking as temporary. Signs of orders normalizing, or early traction from the Rogue Six launches in Canada and Brazil, would back that claim. A sharp deceleration with no timeline for recovery would undercut it.
The offset is margins. Adjusted gross margin rose 65 basis points to 45.6% last quarter, reversing a run of compression despite an unfavorable mix. That helped management raise full-year adjusted EBITDA guidance to about $4 million. Holding gross margin in the mid-40s while sales stall would show the gains reflect cost discipline rather than a one-quarter blip. Updates on the P&L review and on newer products such as Voxy and Aurora, each of which added more than a point of growth last quarter, would strengthen that case.
Sentiment has shifted sharply. Bullish readings have nearly doubled to 68.4% from 35.3% before the last report. The stock trades at $7.13, well above its 200-day moving average of $6.22. It is within about 1% of its post-earnings high of $7.21, testing a breakout, though still below last quarter's $7.43 peak. That leaves less room for a soft quarter than three months ago. The central question is whether the new outlook is a floor. If Inogen meets its flat revenue target, defends its margin gains and reaffirms the reduced full-year range, the reset narrative holds. Another cut, or rental and international weakness spreading faster than management described, would suggest the rally got ahead of the business.